Size:
0.11 MB
(PDF)
Rating:
Boehringer Ingelheim to commence Lux Lung 3 study investigating the role of BIBW 2992* as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations
Boehringer Ingelheim
Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992* as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations
Ingelheim/Germany, 03 August 2009
Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992* as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.
Data from Phase II studies investigating BIBW 2992* and BIBF 1120* in NSCLC patients presented at 13th World Conference on Lung Cancer (WCLC).
*BIBF 1120 and BIBW 2992 are investigational compounds. Their safety and efficacy have not yet been fully established.
Items: 10
Source for healthcare professionals: www.inoncology.com
* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.
© 2012 Boehringer Ingelheim GmbH. All rights reserved.
|
Terms of use
|
Imprint
Boehringer Ingelheim on
